- Home
- NEOV vs MGNX Comparison
NEOV vs MGNX Comparison
Compare NEOV & MGNX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | NEOV | MGNX |
|---|---|---|
| Founded | 2018 | 2000 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Biotechnology: Pharmaceutical Preparations |
| Sector | Miscellaneous | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 137.2M | 115.8M |
| IPO Year | N/A | 2013 |
Fundamental Metrics
Financial Performance| Metric | NEOV | MGNX |
|---|---|---|
| Price | $3.22 | $1.70 |
| Analyst Decision | Hold | Hold |
| Analyst Count | 1 | 5 |
| Target Price | N/A | ★ $3.20 |
| AVG Volume (30 Days) | ★ 1.6M | 846.6K |
| Earning Date | 02-13-2026 | 03-19-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | $18,060,793.00 | ★ $127,626,000.00 |
| Revenue This Year | $148.14 | N/A |
| Revenue Next Year | $6.34 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 615.30 | N/A |
| 52 Week Low | $1.80 | $0.99 |
| 52 Week High | $7.13 | $2.95 |
Technical Indicators
Market Signals| Indicator | NEOV | MGNX |
|---|---|---|
| Relative Strength Index (RSI) | 38.79 | 47.26 |
| Support Level | $3.76 | $1.66 |
| Resistance Level | $4.78 | $1.78 |
| Average True Range (ATR) | 0.57 | 0.10 |
| MACD | -0.15 | -0.02 |
| Stochastic Oscillator | 5.68 | 15.87 |
Price Performance
Historical ComparisonAbout NEOV NeoVolta Inc.
NeoVolta Inc is engaged in designing, manufacturing and sale of high end Energy Storage System which can store and use solar energy via batteries and an inverter at a residential site. Its market place includes solar industry, installers, new construction homebuilders, home remodelers and homeowners.
About MGNX MacroGenics Inc.
Macrogenics Inc is a biotechnology company focused on discovering and developing antibody-based therapeutics for the treatment of cancer. Its product includes MARGENZA, which is for the treatment of adult patients with metastatic HER2-positive breast cancer. It's a pipeline of product candidates designed to target either various tumor-associated antigens or immune checkpoint molecules. The company has three proprietary product candidates in clinical development: lorigerlimab, a bispecific DART molecule that targets checkpoint inhibitors PD-1 and CTLA-4; MGC026, an ADC that targets B7-H3 and delivers a novel topoisomerase I inhibitor (TOP1i)-based linker-payload, and MGC028, an ADC that targets ADAM9 and delivers a novel TOP1i-based linker-payload.